Barclays analyst Matt Miksic raised the firm’s price target on Medtronic (MDT) to $109 from $105 and keeps an Overweight rating on the shares.

Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Medtronic (MDT) to $98 from $106 and keeps an Overweight rating on the ...

Medtronic plc (NYSE:MDT – Get Free Report) was up 0.5% on Monday after Robert W. Baird raised their price target on the stock from $90.00 to $96.00. The stock traded as high as $88.44 and last traded ...

Medtronic (NYSE:MDT – Free Report) had its price target increased by Barclays ... Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $95.85, along ...

Roughly the size of a small paperback book, the external pacemaker was also Medtronic’s first product. Bakken and Medtronic co-founder Palmer J. Hermundslie secured a licensing agreement with ...

Here's a look at Medtronic's past performance and the resulting price change ... Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices ...

Barclays analyst Matt Miksic raised the firm’s price target on Medtronic (MDT) to $109 from $105 and keeps an Overweight rating on the shares. The firm continues to expect accelerating earnings ...